Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.72 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164657 | 1.00 | GRM5 (0.72) | GRM5NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL30510965 | 0.84 | GRM5 (1.00) | GRM5NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL4147283 | 0.84 | GRM5 (1.00) | GRM5NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL15576578 | 0.84 | GRM5 (1.00) | GRM5NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL29781390 | 0.81 | GRM5 (0.84) | GRM5 | |
| SCHEMBL13944075 | 0.81 | GRM5 (0.76) | GRM5 | |
| SCHEMBL7422531 | 0.79 | GRM5 (0.56) | GRM5CYP1A2 | |
| SCHEMBL7422525 | 0.79 | GRM5 (0.56) | GRM5CYP1A2 | |
| SCHEMBL4160148 | 0.78 | GRM5 (0.65) | GRM5NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6431920 | 0.75 | GRM5 (0.58) | GRM5NPC1RAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142318-A1 | PYRIDYLACETYLENES FOR USE AS RADIOTRACERS AND IMAGING AGENTS | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-8674110-B2 | Pyridylacetylenes for use as radiotracers and imaging agents | NOVARTIS AG (CH) | 2014-03-18 | — | — | US | disclosed |
| EP-1670762-B1 | PYRIDYLACETYLENES FOR USE AS RADIOTRACERS AND IMAGING AGENTS | NOVARTIS AG (CH) | 2012-12-05 | — | — | EP | disclosed |
| US-20090010838-A1 | Pyridylacetylenes for Use as Radiotracers and Imaging Agents | NOVARTIS AG (CH) | 2009-01-08 | — | — | US | disclosed |
| EP-1670762-A1 | PYRIDYLACETYLENES FOR USE AS RADIOTRACERS AND IMAGING AGENTS | Novartis AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030723-A1 | PYRIDYLACETYLENES FOR USE AS RADIOTRACERS AND IMAGING AGENTS | NOVARTIS AG (CH) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142318-A1 | PYRIDYLACETYLENES FOR USE AS RADIOTRACERS AND IMAGING AGENTS | B3GNT2, MPI, PLPBP | GRM5 2382/4885NPC1 561/4885RAB9A 1749/4885 |
| US-20090010838-A1 | Pyridylacetylenes for Use as Radiotracers and Imaging Agents | NAT1, PLPBP, AADAC | GRM5 2380/4885NPC1 568/4885RAB9A 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.